Taxol, a natural product first isolated from the Pacific yew tree, is a highly effective anticancer drug used to treat a variety of cancers, including breast, lung, and ovarian cancer. However, Taxol is also known for its severe side effects, including nausea, vomiting, and hair loss.

Now, researchers at the University of California, San Francisco (UCSF) have discovered how Taxol works at the molecular level, a finding that could lead to the development of more effective and less toxic cancer drugs.

The UCSF team, led by chemist Ben Cravatt, found that Taxol binds to a specific protein in cells called tubulin. Tubulin is a key component of the cell's cytoskeleton, a network of filaments and tubules that gives the cell its shape and structure.

When Taxol binds to tubulin, it prevents the tubulin filaments from disassembling, which halts the cell's ability to divide and grow. This is how Taxol kills cancer cells, which divide rapidly and uncontrollably.

"Our discovery provides a new understanding of how Taxol works at the molecular level," said Cravatt. "This knowledge could be used to design new drugs that are more effective and less toxic than Taxol."

The UCSF team is now working on developing new Taxol-like drugs that are more specific for tubulin and that have fewer side effects. These drugs could potentially be used to treat a wider range of cancers and could improve the quality of life for cancer patients.

The discovery of how Taxol works is a major breakthrough in cancer research. This finding could lead to the development of new cancer drugs that are more effective and less toxic, offering new hope for cancer patients.